Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis
Abstract
In 3 Phase 3 studies, 8 weeks' treatment with glecaprevir/pibrentasivr produced an SVR12 in at least 93% of patients with chronic HCV genotype 2, 4, 5, or 6 infection without cirrhosis, with virologic failure in less than 1%. The drug combination had a safety profile comparable to 12 week's treatmen …
Keywords
hepatitis c
National Center for Biotechnology Information
NCBI
NLM
MEDLINE
humans
pubmed abstract
nih
national institutes of health
national library of medicine
treatment outcome
adult
female
male
aged
middle aged
Clinical Trial
Phase III
Randomized Controlled Trial
Double-Blind Method
Multicenter Study
Genotype
antiviral agents / therapeutic use*
chronic / virology
antiviral agents / adverse effects
placebos / administration & dosage
chronic / drug therapy*
hepacivirus / classification
hepacivirus / genetics
Quinoxalines / adverse effects
Quinoxalines / therapeutic use*
sulfonamides / therapeutic use*
federico j mensa
benzimidazoles / adverse effects
sulfonamides / adverse effects
pmid:28951228
doi:10.1016/j.cgh.2017.09.027
tarik asselah
kris v kowdley
benzimidazoles / therapeutic use*
drug-related side effects and adverse reactions / epidemiology
drug-related side effects and adverse reactions / pathology
Access
Citation
ID:
269154
References
Blockchain Verification
Account:
NFT Contract Address:
0x95644003c57E6F55A65596E3D9Eac6813e3566dA
Article ID:
269154
Unique Identifier:
Network:
Scimatic Chain (ID: 481)
Loading...
Blockchain Readiness Checklist
Authors
Abstract
Journal Name
Year
Title
Creates 1,000,000 NFT tokens for this article
Token Features:
- ERC-1155 Standard NFT
- 1 Million Supply per Article
- Transferable via MetaMask
- Permanent Blockchain Record
Scan with Saymatik Web3.0 Wallet
